Rona Therapeutics files IND for RN3161, potent INHBE-siRNA targeting obesity

Rona Therapeutics has filed an Investigational New Drug (IND) application with the Australian Human Research Ethics Committee for RN3161, a GalNAc-conjugated small interfering RNA (siRNA) designed to target the gene INHBE as a therapy for adults with overweight and obesity. According to the company, INHBE produces Activin E in the liver, which regulates fat metabolism, […] The post Rona Therapeutics files IND for RN3161, potent INHBE-siRNA targeting obesity appeared first on Longevity.Technology.